The Latest
-
Win McNamee/Staff via Getty Images
Despite AbbVie’s Botox prowess, underdog Galderma has leveraged soft skills to succeed in aesthetics
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
-
E+ via Getty Images
As pharma M&A ramps up, U.S. execs are bullish on more deals
What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.
-
Stock via Getty Images
4 ways to nail the launch of your cell therapy
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: COTA’s Miruna Sasu
Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.
-
iStock via Getty Images
Turning harp seal contraceptives into a ‘new genre’ of cancer treatments
With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.
-
iStock via Getty Images
Q&AHow real world evidence is impacting rare disease drug development
https://www.gettyimages.com/detail/photo/woman-at-home-using-cell-phone-and-checking-ehr-royalty-free-image/1249041723?adppopup=true
-
Stock via Getty Images
Are Big Pharma CEOs earning their pay?
While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.
-
Mario Tama via Getty Images
The ‘alarming’ spread of Monkeypox — by the numbers
With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’
-
MJ_Prototype via Getty Images
Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?
Companies like Cost Plus Drugs and DiRx can bring generics directly to consumers at a fraction of the price, but whether it’s enough to fix the inflated U.S. healthcare system is yet to be seen.
-
Ivan Balvan via Getty Images
Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires
How these latest executive personnel changes are impacting the industry.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Alloy Therapeutics’ Heather Schwoebel
The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.
-
iStock via Getty Images
Taking probiotics where they’ve never gone before
How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.
-
iStock via Getty Images
‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients
EverythingALS aims to speed drug development through improved diagnostics.
-
Permission granted by Catherine Owen.
Q&AA glimpse inside Bristol Myers Squibb’s integration with Celgene
Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.
-
Olemedia via Getty Images
Q&AHow a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond
WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.
-
Giuseppe Lombardo via Getty Images
Q&APersonalized data could bring PhysIQ to the forefront of clinical trial evolution
The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.
-
iStock via Getty Images
What’s next for Biogen? Here’s what executives are saying
A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?
-
Lisa Maree Williams via Getty Images
Q&ALupus discovery lends clues to the fight against long COVID
So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Applied BioMath's Katie Williams
The 2022 president of Women in Bio is equal parts math and gender parity evangelist.
-
iStock via Getty Images
Democrats think they've found a balance between drug innovation and pricing negotiation
A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.
-
Stock via Getty Images
The earlier the better: New consortium leverages infant screening to accelerate treatment
Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.
-
koto_feja via Getty Images
A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets
The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?
-
Chris Hondros / Staff via Getty Images
Q&ABehind Pfizer's new quest to target a 'transformation' in pharma
A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.
-
Mike Coppola/Staff via Getty Images
With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about
Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.
-
Maddie Meyer / Staff via Getty Images
Moderna's next vax target? A little-known cause of birth defects
How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.
